DENVER–(BUSINESS WIRE)–Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that it was granted Patent No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.
The endocannabinoid system and other physiological systems can potentially mitigate the effects of organophosphate and carbamate toxicity when treated with medicaments affecting these systems in a time and dose-dependent format.
Nexien’s unique process for treating symptoms incorporates a composition comprising tetrahydrocannabinol and cannabidiol formulated for administration by an oral, nasal, buccal, sublingual, parenteral, or any combination thereof.
Alex Wasyl, Nexien’s Chief Executive Officer, stated, “We are pleased to announce a milestone in Nexien’s patent development – the granting of our first patent in Israel. While we continue to build our entire patent estate, this achievement puts Nexien in a better position to advance our clinical investigation of cannabinoid drug formulations and delivery systems for the acute treatment during exposure of poisoning from organophosphorus nerve agents.”